{
    "clinical_study": {
        "@rank": "139711", 
        "arm_group": {
            "arm_group_label": "1:Enzalutamide", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The objective of this study is to evaluate the efficacy and safety of enzalutamide treatment\n      in patients with progressive metastatic castration-resistant prostate cancer previously\n      treated with abiraterone acetate."
        }, 
        "brief_title": "A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Castration-Resistant Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has histologically confirmed adenocarcinoma of the prostate without\n             neuro-endocrine differentiation or small cell features.\n\n          -  Subject has metastatic disease documented by bone scan or by soft tissue disease\n             observed by Computed Tomography/Magnetic Resonance Imaging (CT/MRI).\n\n          -  In the setting of castrate levels of testosterone \u22641.7 nmol/L (or \u226450 ng/dL), subject\n             has progressive disease at study entry defined as PSA rise determined by a minimum of\n             2 rising PSA levels with an interval of \u2265 1 week between each assessment. The PSA\n             value at the screening visit should be \u2265 2 ng/mL WITH or WITHOUT:\n\n               -  Soft tissue disease progression defined by Response Evaluation Criteria In Solid\n                  Tumors (RECIST 1.1) at screening. Measurable disease is not required for entry.\n                  Lymph nodes \u2265 2 cm are considered measurable disease (Prostate Cancer Clinical\n                  Trials Working Group (PCWG2)).\n\n               -  Bone disease progression defined by at least 2 new lesions on bone scan at\n                  screening.\n\n          -  Subject must have received a minimum of 6 months of treatment with abiraterone\n             acetate and has discontinued use at least 4 weeks prior to start of study drug at Day\n             1.\n\n          -  If the subject has received previous treatment with chemotherapy for prostate cancer,\n             this must be limited to no more than one prior line of docetaxel, and must have been\n             used prior to abiraterone acetate therapy.\n\n          -  Subject receives and will continue to receive ongoing androgen deprivation with\n             Luteinizing-hormone-releasing hormone (LHRH) analogue therapy throughout the course\n             of the study or has had a bilateral orchiectomy.\n\n          -  Subject is asymptomatic or mildly symptomatic from prostate cancer:\n\n               -  The score on Brief Pain Inventory - Short Form (BPI-SF) Question #3 must be < 4.\n\n               -  No use of opiate analgesics for prostate cancer-related pain currently or\n                  anytime within 4 weeks prior to screening.\n\n        Exclusion Criteria:\n\n          -  Subject has prior use of ketoconazole for the treatment of prostate cancer.\n\n          -  Subject has prior use of cabazitaxel.\n\n          -  Subject has prior use of enzalutamide.\n\n          -  Subject has received ANY anti-neoplastic therapy (including antiandrogens and\n             chemotherapy) following abiraterone acetate discontinuation and prior to start of\n             study drug at Day 1.\n\n          -  Subject has a known or suspected hypersensitivity to enzalutamide, or any components\n             of the formulation used.\n\n          -  Subject has known or suspected brain metastases or active leptomeningeal disease.\n\n          -  Subject has history of seizure or any condition that may predispose to seizure (e.g.,\n             prior stroke or significant brain trauma)."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02116582", 
            "org_study_id": "9785-CL-0410", 
            "secondary_id": "2013-002271-17"
        }, 
        "intervention": {
            "arm_group_label": "1:Enzalutamide", 
            "description": "Oral", 
            "intervention_name": "Enzalutamide", 
            "intervention_type": "Drug", 
            "other_name": [
                "MDV3100", 
                "Xtandi"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Metastatic Castration-Resistant Prostate Cancer", 
            "Enzalutamide", 
            "Xtandi", 
            "MDV3100", 
            "Abiraterone"
        ], 
        "lastchanged_date": "April 15, 2014", 
        "number_of_arms": "1", 
        "official_title": "A Multi-center, Single Arm Study of Enzalutamide in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate", 
        "overall_contact": {
            "email": "contact@nl.astellas.com", 
            "last_name": "Global Clinical Science", 
            "phone": "+31 (0)71 5455 500"
        }, 
        "overall_official": {
            "affiliation": "Astellas Pharma BV", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Netherlands: Medicines Evaluation Board (MEB)", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "rPFS is defined as the time interval from first dose to objective evidence of radiographic disease progression or death for any reason, whichever occurs first", 
            "measure": "Radiographic progression-free survival (rPFS)", 
            "safety_issue": "No", 
            "time_frame": "until subject discontinuation (up to 2 years)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02116582"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "until subject discontinuation (up to 2 years)"
            }, 
            {
                "measure": "Prostate-specific antigen (PSA) response", 
                "safety_issue": "No", 
                "time_frame": "until subject discontinuation (up to 2 years)"
            }, 
            {
                "measure": "Time to PSA progression", 
                "safety_issue": "No", 
                "time_frame": "until subject discontinuation (up to 2 years)"
            }, 
            {
                "measure": "Safety assessed through evaluation of Adverse Events and Serious Adverse Events, safety laboratory tests, physical examination and vital signs", 
                "safety_issue": "No", 
                "time_frame": "Time from signing informed consent to 30 days after last dose of study drug."
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "collaborator": {
                "agency": "Medivation, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Astellas Pharma Europe B.V.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}